Biomedical subjects

Chang Tan

Publications and source records attributed to Chang Tan.

3 recordsLinked to original sources

PubMed2026

Long-day photoperiod promotes growth of pea (Pisum sativum L.) via auxin biosynthesis and polar transport.

Photoperiodic sensitivity is an essential factor that may affect agricultural practices under current climate scenarios. This study used pea (Pisum sativum) to examine effects of varying photoperiods on growth and photosynthetic parameters and then reveal the mechanistic basis of this process by linking them with tissue-specific distribution of auxin and regulation of related genes. This was achieved by transcriptome sequencing, genome-wide gene family identification, and expression pattern analysis. Best results in terms of growth and yield were obtained with a 20 h/4 h light/dark photoperiod and these plants had the highest content of endogenous indole-3-acetic acid (IAA) in both the shoot apex and the root. Genes consistently upregulated with prolonged light exposure were significantly enriched in pathways related to light signal transduction, photosynthetic carbon metabolism, and phytohormone signal transduction. Through genome-wide identification, we characterized the TAA/TAR and YUCCA families (key gene families involved in auxin biosynthesis) as well as the PIN family (responsible for auxin polar transport) in pea. Extending the light duration positively affected expression of several genes related to auxin biosynthesis and transport, among them members of the Elongated Hypocotyl (HY) and Phytochrome-Interacting Factor (PIF) families being key light-induced transcription factors, PsTAR2, the principal gene regulating auxin biosynthesis, as well as PsPIN4, PsPIN5, PsPIN11, and PsPIN13 which mediate polar auxin transport. By elucidating mechanisms underlying the coordinated regulation of pea growth by light and auxin, this work provides a significant reference for photoperiod research on long-day crops for both protected- and field-based horticulture.

Auxin↗

PubMed2026

Genomic analysis of an Arctic marine Tenacibaculum sp. SM2510 reveals its genetic potential for glutathione utilization.

Glutathione is a key intracellular antioxidant, playing a crucial role in resisting oxidative stress and maintaining cellular redox homeostasis. However, the glutathione metabolic capacity of Tenacibaculum remains poorly characterized. In this study, a Gram-stain-negative bacterium, Tenacibaculum sp. SM2510, was isolated from seawater collected from Kongsfjorden, Svalbard, Norway. Genome sequencing revealed that the strain possesses a single circular chromosome of 2,904,982 bp with a G + C content of 31.44%, encoding 2564 protein-coding genes. Genomic analysis indicates that Tenacibaculum sp. SM2510 may directly take up extracellular oxidized glutathione (GSSG) and reduce it to reduced glutathione (GSH) through a reductive pathway, which potentially allows the strain to alleviate the accumulation of reactive oxygen species (ROS) caused by strong ultraviolet radiation and low temperature in polar environments. Furthermore, genomic analysis predicts that the strain degrades GSH to produce essential life-sustaining substances. In conclusion, these results suggest that Tenacibaculum sp. SM2510 may potentially utilize exogenous glutathione for both antioxidant defense and nutrient acquisition through direct GSH degradation, providing new insights into the environmental adaptive evolution of polar marine bacteria.

Tenacibaculum↗

PubMed2025

AAV gene therapy for autosomal recessive deafness 9: a single-arm trial.

Gene therapy for congenital deafness has shown promising results in children but lacks data in older populations. We conducted a single-arm trial of adeno-associated virus (AAV)-OTOF gene therapy using the Anc80L65 capsid in ten participants with autosomal recessive deafness 9 aged 1.5 to 23.9 years at five sites in China. The primary endpoints were safety and tolerability within 5 years, and secondary endpoints assessed auditory function. Initial findings from the ten patients with 6-12 months of follow-up, including one patient who received two injections, revealed that the therapy was well tolerated, with 162 grade I/II adverse events. Decreased neutrophil percentage was the most common event (16 of 162). All ten participants had at least 6 months of follow-up and improved their pure-tone-average hearing level from baseline 106 ± 9 (mean ± s.d.) to 52 ± 30 decibels (dB). Other secondary endpoints showed similar improvements, including the average click auditory brainstem response (ABR) threshold, the tone-burst ABR threshold and the auditory steady-state response (101 ± 1 to 48 ± 26 dB, 91 ± 4 to 57 ± 19 dB and 80 ± 14 to 64 ± 21 dB, respectively). Post hoc analyses were conducted to evaluate the timecourse and factors contributing to the hearing improvement. Therapeutic effect was rapid, taking 1 month to achieve most of the overall hearing improvement. On an individual level, click and tone-burst ABR thresholds, but not the auditory steady-state response, reliably predicted the behavioral pure-tone-average thresholds after 4 months (R2 = 0.68, 0.73 and 0.17, respectively). An age-dependent therapeutic effect was observed, with optimal outcomes in 5- to 8-year-olds. These preliminary results show that AAV-OTOF was safe and well tolerated in patients ranging from toddlerhood to adulthood. The trial remains ongoing and requires extended follow-up to confirm the long-term safety and efficacy. ClinicalTrials.gov registration: NCT05901480 .

Humans↗